Losartan Potassium
Brands: Cozaar · Losortan Potassium · Losartan Potassium
34 active makers
soon
soon
soon
soon
US acquisition costNADAC · per unit
Average across 87 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Brands: Cozaar · Losortan Potassium · Losartan Potassium
Average across 87 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Bryant Ranch Prepack | repackager | 71 | SUPPLYING |
| Proficient Rx LP | repackager | 32 | SUPPLYING |
| Preferred Pharmaceuticals Inc. | repackager | 26 | SUPPLYING |
| A-S Medication Solutions | repackager | 24 | SUPPLYING |
| Alembic Pharmaceuticals Limited | generic | 24 | SUPPLYING |
| Aphena Pharma Solutions - Tennessee, LLC | repackager | 21 | SUPPLYING |
| REMEDYREPACK INC. | repackager | 17 | SUPPLYING |
| NuCare Pharmaceuticals,Inc. | repackager | 16 | SUPPLYING |
| Zydus Lifesciences Limited | generic | 15 | SUPPLYING |
| Zydus Pharmaceuticals USA Inc. | generic | 15 | SUPPLYING |
| Camber Pharmaceuticals, Inc. | generic | 15 | SUPPLYING |
| PD-Rx Pharmaceuticals, Inc. | repackager | 14 | SUPPLYING |
| Macleods Pharmaceuticals Limited | generic | 12 | SUPPLYING |
| Solco Healthcare US, LLC | unknown | 11 | SUPPLYING |
| Direct_Rx | repackager | 9 | SUPPLYING |
+ 19 more labelers
Shortages, recalls, and registration changes attached to this drug concept.
Presence of Foreign Substance: Presence of a small piece of blue plastic embedded in the tablet. — Recalling firm: Strides Pharma Inc. — Nationwide in the USA.
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits — Recalling firm: PD-Rx Pharmaceuticals, Inc. — Nationwide
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits — Recalling firm: PD-Rx Pharmaceuticals, Inc. — Nationwide
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits — Recalling firm: PD-Rx Pharmaceuticals, Inc. — Nationwide
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits — Recalling firm: Strides Pharma Inc. — Nationwide
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits — Recalling firm: Strides Pharma Inc. — Nationwide
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits — Recalling firm: Strides Pharma Inc. — Nationwide
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits — Recalling firm: Macleods Pharma Usa Inc — Product was distributed nationwide.
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits — Recalling firm: Macleods Pharma Usa Inc — Product was distributed nationwide.
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits — Recalling firm: Macleods Pharma Usa Inc — Product was distributed nationwide.
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. — Recalling firm: Macleods Pharma Usa Inc — Nationwide
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. — Recalling firm: Macleods Pharma Usa Inc — Nationwide
CGMP deviation: Product found to contain trace amounts of NMBA — Recalling firm: PD-Rx Pharmaceuticals, Inc. — AK, AZ, CA, CO, FL, KY, MA, MI, MN, NC, OH, OR, WI, WY
CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient — Recalling firm: Camber Pharmaceuticals Inc — Nationwide
CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient — Recalling firm: Camber Pharmaceuticals Inc — Nationwide
CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient — Recalling firm: Camber Pharmaceuticals Inc — Nationwide
Failed Content Uniformity Specifications; Dry mix failed blend uniformity. — Recalling firm: Micro Labs Usa, Inc S — U.S. Including: New York